Skip to main content
Clinical Trials/EUCTR2010-018303-28-FR
EUCTR2010-018303-28-FR
Active, not recruiting
Not Applicable

Etude pilote des signes électro-encéphalographiques de réveil secondaire à l’injection de sugammadex : évaluation par l’enregistrement de l’Index Bispectral et du NeuroSENSE (étude prospective, randomisée, monocentrique et réalisée en double aveugle) - Suggamadex-Réveil

Hopital Foch0 sitesMarch 16, 2010
DrugsBridion

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Hopital Foch
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 16, 2010
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for general anesthesia
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \- Age under 18 years
  • \- Pregnancy, non menopausal woman
  • \- Allergy to propofol, soybeans or peanuts
  • \- Allergy to sufentanil, remifentanil, morphine, or to a component
  • \- Hypersensibility to sufentanil, remifentanil or to a derivate of fentanyl
  • \- Allergy to rocuronium or to bromure ion
  • \- History of a central neurological disorder or of a lesion cerebral
  • \- Patients receiving a psychotropic treatment
  • \- Presence of a pace\-maker
  • \- Hypersensibility to sugammadex or to a component

Outcomes

Primary Outcomes

Not specified

Similar Trials